Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Jacobio Pharmaceuticals has recently showcased promising clinical data at the 2024 ASCO Annual Meeting, indicating significant treatment efficacy of its novel combination therapy for non-small cell lung cancer (NSCLC). The company’s KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor JAB-3312, demonstrated a high objective response and disease control rate, with a manageable safety profile. This milestone has led to the initiation of a Phase III trial in China, and the monotherapy has received Priority Review by China’s drug regulatory authority.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
